Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program
12:00pm, Wednesday, 22'nd Apr 2020
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,
Will CorMedix Continue to Surge Higher?
03:52pm, Tuesday, 14'th Apr 2020
As of late, it has definitely been a great time to be an investor CorMedix
Edited Transcript of CRMD earnings conference call or presentation 16-Mar-20 8:30pm GMT
10:44am, Monday, 30'th Mar 2020
Q4 2019 CorMedix Inc Earnings Call
Former England international Kevin Davies signs up to help NHS in coronavirus battle
12:34pm, Wednesday, 25'th Mar 2020
Former England international Kevin Davies has offered his help to the NHS during the coronavirus crisis.
CorMedix, Inc. (NYSEMKT:CRMD) Just Reported Earnings, And Analysts Cut Their Target Price
10:32am, Friday, 20'th Mar 2020
CorMedix, Inc. (NYSEMKT:CRMD) missed earnings with its latest yearly results, disappointing overly-optimistic...
Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
02:40pm, Thursday, 19'th Mar 2020
Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
02:40pm, Thursday, 19'th Mar 2020
Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
What Did CorMedix, Inc.'s (NYSEMKT:CRMD) CEO Take Home Last Year?
11:19am, Thursday, 19'th Mar 2020
Khoso Baluch became the CEO of CorMedix, Inc. (NYSEMKT:CRMD) in 2016. This analysis aims first to contrast CEO...
H.C. Wainwright Sticks to Their Buy Rating for Cormedix (CRMD)
11:24am, Wednesday, 18'th Mar 2020
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cormedix (CRMD), with a price target of $14.00. The company's
B. Riley FBR Maintains Buy on Cormedix, Lowers Price Target to $10
11:09am, Wednesday, 18'th Mar 2020BRIEF-Cormedix Q4 Loss Per Share $0.21
10:41pm, Monday, 16'th Mar 2020
* . REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
08:05pm, Monday, 16'th Mar 2020
Company in process of submitting New Drug Application (NDA) for Neutrolin® for prevention of catheter-related blood stream infections via a rolling review granted by FDA.
